Вплив ранолазину на перебіг ішемічної хвороби серця після черезшкірного коронарного втручання

О.А. Єпанчінцева, О.Й. Жарінов, І.В. Шклянка

Література  

1. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation. 2016;133(1):39–47. doi: 10.1161/CIRCULATIONAHA.115.019768.
2. Antzelevitch C, Burashnikov A, Sicouri S. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281–1290. doi: 10.1016/j.hrthm.2011.03.045.
3. Bonello L, Sbragia Р, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart (British Cardiac Society). 2007;93(6):703–707. doi: 10.1136/hrt.2006.107524.
4. Calcagno S, Infusino F, Dettori O, Taccheri T, Bruno P, Maestrini V, Sardella G, Mancone M, Fedele F. Effects of Ivabradine on Residual Myocardial Ischemia after PCI Evaluated by Stress Echocardiography. Cardiology Research and Practice. 2019;38:1–7. doi: 10.1155/2019/9185876.
5. Calcagno S, Infusino F, Salvi N, Taccheri T, Colantonio R, Bruno E, Birtolo LI, Severino P, Lavalle C, Pucci M, Sardella G, Mancone M, Fedele F. The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization. J Clin Med. 2020;9(7):2110. doi: 10.3390/jcm9072110.
6. Calcagno S, Taccheri T, Carnesale R. et al. Complete coronary revascularization in different clinical settings is not enough: role of ranolazine. JАСС. 2014;63(12):А1596. doi: 10.1016/S0735-1097(14)61599-0.
7. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–316. doi: 10.1001/jama.291.3.309.
8. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382. doi: 10.1016/j.jacc.2003.11.045.
9. De Vecchis R, Ariano C, Giasi A, Cioppa C. Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardioangiol. 2018;66(3):349–359.
10. Ferrari R, Ford I, Fox K. et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020. Published Online August 30. doi: 10.1016/ S0140-6736(20)31790-6.
11. Fihn SD, Gardin JM, Abrams J. et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation. 2012;126:e354–e471.
12. Gaglia MA, Torguson R, Lipinski MJ. et al. Frequency of Angina Pectoris After Percutaneous Coronary Intervention and the Effect of Metallic Stent Type. Am J Cardiol. 2016;117 (4):526–531. doi: 10.1016/j.amjcard.2015.11.036.
13. Han Y, Xu B, Fu G. et al. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. J Am Coll Cardiol Cardiovasc Interv. 2018;11(3):260–272.
14. Iqbal SMM, Ahsan SA, Jahan KA, Eva SN. Effectiveness of Ranolazine to Prevent Myocardial Injury During Elective Percutaneous Coronary Intervention. AKMMC. 2019;10(1):43–49. doi: 10.3329/akmmcj.v10i1.43664.
15. Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477. doi: 10.1093/eurheartj/ehz425.
16. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992;13(8):1109–1115. doi: 10.1093/oxfordjournals.eurheartj.a060322.
17. Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome. Eur Heart J. 1993;14(Suppl. G):34–40.
18. Malhotra A, Cheema Y, Patel D. et al. Effect of ranolazine on activity level in patients with angina after fractional flow reserve based deferred intervention. JАСС. 2019;73(1):141. doi: 10.1016/S0735-1097(19)30749-1.
19. Manolis AJ, Poulimenos LE, Ambrosio G. et al. Medical treatment of stable angina: A tailored therapeutic approach. Intern J Cardiology. 2016;220:445–453.
20. Maron DJ, Hochman JS, Reynolds HR. et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. New Engl J Med. 2020;382:1395–407.
21. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(Iss. 38):2949–3003. doi: 10.1093/eurheartj/eht296.
22. Mukherjee D. Management of refractory angina in contemporary era. Eur Heart J. 2013;34:2655–2657.
23. Pelliccia F, Pasceri V, Marazzi G. et al. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. 2012;163(6):1019–1023. doi: 10.1016/j.ahj.2012.03.018.
24. Redfors B, Généreux P. Ranolazine following percutaneous coronary intervention: For whom? For what? Exp Review Cardiovasc Therapy. 2016;14(5):541–543. doi: 10.1586/14779072.2016.1150176.
25. Sardella G, Mancone M, Stio RE. et al. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients with Diabetes Mellitus. Circulation. 2017;136:602–604. doi: 10.1161/CIRCULATIONAHA.117.028745.
26. Sardella G, Stella P, Chiarito M. et al. Clinical outcomes with reservoir-based polymer-free amphilimus-elutingstents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry. Catheter Cardiovasc Interv. 2018;91:884–891. doi: 10.1002/ccd.27187.
27. Scirica B, Morrow D, Hod H. et al. Effect of ranolazine an antianginal agent with novel electrophysiological properties on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome (from MERLIN-TIMI 36 the randomized controlled trial). Circulation. 2007;116:1647–1652. doi: 10.1161/CIRCULATIONAHA.107.724880.
28. Shibata M, Ueshima K, Harada M. et al. Effect of magnesium sulphate pre-treatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction. Angiology. 1999;50(7):573–582.
29. Stone PH, Gratsiansky NA, Blokhin A. et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575.
30. The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New Engl J Med. 2009;360:2503–2515.
31. Timmis A, Townsend N, Gale C. et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12–85. doi: 10.1093/eurheartj/ehz859.
32. Weisz G, Généreux P, Iñiguez A. et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136–145. doi: 10.1016/S0140-6736(15)00459-6.
33. Wilson SR, Scirica BM, Braunwald E. еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double- blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510–1516. doi: 10.1016/j.jacc.2009.01.037.
34. World Health Organization Website http:// www.who.int. Accessed March 26. 2012.
35. Zarifis J, Grammatikou V, Kallistratos M, Katsivas A. Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization. Angiology. 2017;68(1):10–18. doi: 10.1177/0003319716630499.

Використання персоналізованої схеми введення фентанілу під час стентування коронарних артерій

Д.О. Дзюба

Література   

1. Dziuba DО, Byshovets SM, Loskutov OA. Establishing the optimal depth of analgesia during coronary artery stenting. Pain, Anaesthesia and Intensive Care. 2020;3 (92):17–24. doi: 10.25284/2519-2078.3(92).2020.211432.
2. Dziuba DО, Zhurovska UM, Loskutov OA. Issues of anesthesia in interventional cardiology. Emergency Medicine. 2017;1(80):125–128. doi: 10.22141/2224-0586.1.80.2017.94464.
3. Zozulia IS, Zozulia AI. Epidemiology of cerebrovascular diseases in Ukraine. Ukr. Med. J. 2011;5:38–41.
4. Kozlov AI, Kozlova MA. Cortisol as a marker of stress. Human physiology. 2014;40:123–123. doi: 10.7868/S013116461402009X.
5. Armario A, Marti O, Molina T, de Pablo J, Valdes M. Acute stress markers in humans: response of plasma glucose, cortisol and prolactin to two examinations differing in the anxiety they provoke. Psychoneuroendocrinology. 1996;21(1):17–24. doi: 10.1016/0306-4530(95)00048-8.
6. Benjamin EJ, Virani SS, Callaway CW. et al. Heart disease and stroke statistics – 2018 update: A Report From the American Heart Association. Circulation. 2018;137(12):67–492. doi: 10.1161/CIR.0000000000000558.
7. Burns SM, Cunningham, CW, Mercer SL. DARK classics in chemical neuroscience: fentanyl. ACS Chemical Neuroscience. 2018;9(10):2428–2437. doi: 10.1021/acschemneuro.8b00174.
8. Choi L, Ferrell BA. Vasilevskis EE. et al. Population pharmacokinetics of fentanyl in the critically ill. Critical Care Medicine. 2016;44(1):64. doi: 10.1097/CCM.0000000000001347.
9. Dong H, Zhang FJ, Wang FY, Wang YY, Guo J, Kanhar GM, ... Chen X. Simultaneous on-line monitoring of propofol and sevoflurane in balanced anesthesia by direct resistive heating gas chromatography. J Chromatography. 2017;1506:93–100. https://doi.org/10.1016/j.chroma.2017.05.001.
10. Drummer OH. Fatalities caused by novel opioids: a review. Forensic Sci Res. 2019;4(2) :95–110. doi: 10.1080/20961790.2018.1460063.
11. Hagos FT, Horvat CM, Au AK, Conley YP, Li L, Poloyac SM, Kochanek PM, Clark RSB, Empey PE Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. Clin Pharmacokinet. 2019;58:1567–1576. doi: 10.1007/s40262-019-00773-1.
12. Haslam PJ, Yap B, Mueller PR, Lee MJ. Anesthesia practice and clinical trends in interventional radiology: a European survey. Cardiovasc Interven Radiology. 2000;23(4):256–261. doi: 10.1007/s002700010065.
13. Koolen SL, Van der Rijt CC. Is there a role for pharmacogenetics in the dosing of fentanyl? Pharmacogenomics. 2017;18(5):417–419. doi: 10.2217/pgs-2017-0022.
14. Michael ML, Lennox PH. Sedation and analgesia in the interventional radiology department. J Vasc Interv Radiology. 2003;14 (9):1119–1128.
15. Movsisyan NK, Vinciguerra M, Medina-Inojosa JR, Lopez-Jimenez F. Cardiovascular Diseases in Central and Eastern Europe: A Call for Morge Surveillance and Evidence-Based Health Promotion. Annals of Global Health. 2020;86(1).
16. Mueller PR, Wittenberg KH, Kaufman JA, Lee MJ. Patterns of anesthesia and nursing care for interventional radiology proceggdures: a national survey of physician practices and preferences.. Radiology. 1997;202(2):339–343. doi: 10.1148/radiology.202.2.9015053.
17. Norman E, Kindblom JM, Rane A. et al. Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. Acta Paediatrica. 2019;108(8):1441–1446. doi: 10.1111/apa.14744.
18. Schifano F, Chiappini S, Corkery JM, Guirguis A. Assessing the 2004–2018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front Pharmacology. 2019. doi: 10.3389/fphar.2019.00046.
19. Schug SA, Ting S. Fentanyl formulations in the management of pain: an update. Drugs. 2017;77(7):747–763. doi: 10.1007/s40265-017-0727-z.
20. Sekhri NK, Cooney MF. Opioid metabolism and pharmacogenetics: clinical implications. J Peri Anesthesia Nursing. 2017;32(5):497–505. doi: 10.1016/j.jopan.2017.07.005.
21. Smith HS, Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacology. 2014;722:67–78. doi: 10.1016/j.ejphar.2013.09.074.
22. Solhaug V, Molden E. Individual variability in clinical effect and tolerability of opioid analgesics – importance of drug interactions and pharmacogenetics. Scandinavian J Pain. 2017;17(1):193–200. doi: 10.1016/j.sjpain.2017.09.009.
23. Vari A, Gangi A. Anesthesia practices for interventional radiology in Europe. Cardiovasc Intervent Radiology. 2017;40:803–813. doi: 10.1007/s00270-017-1576-6.
24. Versaci F, Gaspardone A, Tomai F, Proietti I, Crea F, Chiariello L, Gioffrè PA. Chest pain after coronary artery stent implantation. Amer J Cardiology. 2002;89(5):500–504. doi: 10.1016/s0002-9149(01)02287-1.
25. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR. et al. Heart disease and stroke statistics 2020 update: a report from the American Heart Association. Circulation. 2020;141:E139–E596. doi: 10.1161/CIR.0000000000000757.
26. Yiannakopoulou E. Pharmacogenomics and opioid analgesics: clinical implications. Intern J Genomics. 2015;2015. doi: 10.1155/2015/368979.
27. Zawilska JB. An expanding world of novel psychoactive substances: opioids. Front Psychiatry. 2017;8:110. doi: 10.3389/fpsyt.2017.00110.

Вплив мультимодальної малоопіоїдної анестезії на динаміку анексину V у плазмі крові хворих, яким виконують кардіохірургічні втручання

С.Р. Маруняк, О.А. Лоскутов, О.М. Дружина, І.Р. Малиш, Н.В. Коротчук

Література   

1. De Jong RCM, Pluijmert NJ, de Vries MR. et al. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response. Sci Rep. 2018;8(1):6753. doi: 10.1038/s41598-018-25143-y.
2. Ewing MM, de Vries MR, Nordzell M. et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol. 2011;31(1):95–101. doi: 10.1161/ATVBAHA.110.216747.
3. Kenis H, Zandbergen HR, Hofstra L. et al. Annexin A5 uptake in ischemic myocardium: demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging. J Nucl Med. 2010;51(2):259–267. doi: 10.2967/jnumed.109.068429.
4. Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arterioscler Thromb Vasc Biol. 2009;29(7):1031–1038. doi: 10.1161/ATVBAHA.108.165522.
5. Matsuda R, Kaneko N, Kikuchi M. et al. Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. Resuscitation. 2003;57(2):171–177. doi: 10.1016/s0300-9572(03)00034-0.
6. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res. 1999;85(2):185–199. doi: 10.1006/jsre.1999.5660.
7. Ravassa S, García-Bolao I, Zudaire A. et al. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Res. 2010;88(2):304–313. doi: 10.1093/cvr/cvq183.
8. Ravassa S, González A, López B. et al. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J. 2007;28(22):2785–2791. doi: 10.1093/eurheartj/ehm370.
9. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53(6):527–532. doi: 10.1007/s000180050067.
10. Ruifrok WT, Westenbrink BD, de Boer RA. et al. Apoptosis during CABG surgery with the use of cardiopulmonary bypass is prominent in ventricular but not in atrial myocardium. Neth. Heart J. 2010;18(5):236–242. doi: 10.1007/BF03091769.
11. Shojaie M, Sotoodah A, Roozmeh S. et al. Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction. Thrombosis J. 2009;7:13. doi: 10.1186/1477-9560-7-13.
12. Van Genderen HO, Kenis H, Hofstra L. et al. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta. 2008;1783(6):953–963. doi: 10.1016/j.bbamcr.2008.01.030.
13. Van Heerde WL, Sakariassen KS, Hemker HC. et al. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler Thromb. 1994;14(5):824–830. doi: 10.1161/01.atv.14.5.824.
14. Wang X, Guo Z, Ding Z, Mehta JL. Inflammation, autophagy, and apoptosis after myocardial infarction. J Am Heart Assoc. 2018;7(9):e008024. doi: 10.1161/JAHA.117.008024.

Оригінальний метод лікування аневризми висхідного відділу аорти

В.Б. Демянчук, В.В. Погребняк, О.В. Зеленчук, О.І. Кваша, Б.М. Тодуров

Література    

1. Ang KL, Raheel F, Bajaj A, Ang K-L, Raheel F, Bajaj A, Sosnowski A, Galiñanes M. Early impact of aortic wrapping on patients undergoing aortic valve replacement with mild to moderate ascending aorta dilatation. J Cardiothorac Surg. 2010;5:58. doi: 10.1186/1749-8090-5-58.
2. Arsan S, Akgun S, Kurtoglu N, Yildirim T, Tekinsoy B. Reduction aortoplasty and external wrapping for moderately sized tubular ascending aortic aneurysm with concomitant operations. Ann Thorac Surg. 2004;78:858–861. doi: 10.1253/circj.CJ-10-0792.
3. Egloff L, Rothlin M, Kugelmeier J, Senning A, Turina M. The ascending aortic aneurysm: replacement or repair? Ann Thorac Surg. 1982;34:117–124. doi: 10.1016/s0003-4975(10)60871-5.
4. Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol. 1995;48:1289–1298.doi: 10.1016/0895-4356(95)00045-3.
5. González-Santos JM, Arnáiz-García ME. Wrapping of the ascending aorta revisited — is there any role left for conservative treatment of ascending aortic aneurysm? J Thorac Dis. 2017; 9(Suppl 6): S488–S497. doi: 10.21037/jtd.2017.04.57.
6. Laux ML, Ostovar R, Braun C. et al. Wrapping in ascending aortic aneurysms as an alternative for replacement: is it beneficial? Thorac Cardiovasc Surg. 2020;68(4):322–327. doi: 10.1055/s-0039-1700530.
7. Lee SH, Kim JB, Kim DH. et al. Management of dilated ascending aorta during aortic valve replacement: valve replacement alone versus aorta wrapping versus aorta replacement. J. Thorac. Cardiovasc. Surg. 2013;146:802–809. doi: 10.1253/circj.cj-14-0933.
8. Min Suk Choi, Dong Seop Jeong, Hae Young Lee et al. Aortic Wrapping for a Dilated Ascending Aorta in Bicuspid Aortic Stenosis. Circ J. 2015; 79: 778–784. doi: 10.1253/circj.CJ-14-0933.
9. Nishimura RA, Otto CM, Bonow RO. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice et al. Guidelines. J Am Coll Cardiol. 2014; 63: 2438–2488. doi: 10.1161/CIR.0000000000000029.
10. Park J.Y, Shin J.K, Chung J.W. et al. Short-term Outcomes of Aortic Wrapping for Mild to Moderate Ascending Aorta Dilatation in Patients Undergoing Cardiac Surgery. Korean. J Thorac Cardiovasc Surg. 2012;45:148–154. doi: 10.5090/kjtcs.2012.45.3.148.
11. Plonek T, Dumanski A, Obremska M, Kustrzycki W. First beating-heart valve-sparing aortic root repair: a “corset” technique. Ann Thorac Surg. 2015;99:1464–1466. doi: 10.1016/j.athoracsur.2014.11.062.
12. Robicsek F. A new method to treat fusiform aneurysms of the ascending aorta associated with aortic valve disease: an alternative to radical resection. Ann Thorac Surg. 1982;34:92–94. doi: 10.1016/s0003-4975(10)60860-0. 

Безпосередні результати ендопротезування черевного відділу аорти у хворих з несприятливою проксимальною шийкою аневризми

С.М. Фуркало, В.А. Кондратюк, О.А. Власенко, І.В. Хасянова, А.В. Хохлов, П.А. Гиндич, І.А. Мазанович, О.О. Пустинцев

Література     

1. Furkalo SM, Khokhlov AV. The first experience of clinical application of Aptus Heli-FX mechanical fixation devices during endovascular prosthetics of the abdominal aorta. Clinical surgery. 2019;86(3):71–73.
2. Ahn S. Adjunctive Procedures for Challenging Endovascular Abdominal Aortic Repair: When Needed and How Effective? Ahn S Vasc Specialist Int. 2020;36(1):7–14. doi: 10.5758/vsi.2020.36.1.7.
3. Antoniou GA, Georgiadis GS, Stavros AA, Ganesh K. A meta-analysis of outcomes of endovascular abdominal aortic aneurysm repair in patients with hostile and friendly neck anatomy. J Vasc Surg. 2013;57:527–538. doi: 10.1016/j.jvs.2012.09.050.
4. De Vries JP, Van De Pavoordt HD, Jordan WDJr. Rationale of Endo Anchors in abdominal aortic aneurysms with short or angulated necks. J Cardiovasc Surg. (Torino). 2014;55(1):103–107.
5. Donas KP, Lee JT, Lachat M. et al, on behalf of the PERICLES investigators. Collected World Experience About the Performance of the Snorkel/Chimney Endovascular Technique in the Treatment of Complex Aortic Pathologies. The PERICLES Registry Annals of Surgery.  2015;262(3):546–553. doi: 10.1097/SLA.0000000000001405.
6. Gallitto E, Gargiulo M, Freyrie A. et al. The endovascular treatment of juxta-renal abdominal aortic aneurysm using fenestrated endograft: early and mid-term results. J Cardiovasc Surgery. 2019;60(2):237–244. doi: 10.23736/S0021-9509.16.09049-2.
7. Goudeketting SR, van Noort K, Ouriel K. et al. Influence of aortic neck characteristics on successful aortic wall penetration of EndoAnchors in therapeutic use during endovascular aneurysm repair. J Vasc Surg. 2018;68(4):1007–1016. doi: 10.1016/j.jvs.2018.01.039.
8. Hiramoto JS, Chang CK, Reilly LM. et al. Outcome of renal stenting for renal artery coverage during endovascular aortic aneurysm repair. J Vasc Surg. 2009;49:1100–1106. doi: 10.1016/j.jvs.2008.11.060.
9. Jordan WD, Mehta M, Ouriel K. et al. One-year results of the ANCHOR trial of EndoAnchors for the prevention and treatment of aortic neck complications after endovascular aneurysm repair. Vascular. 2016;24(2):177–186. doi: 10.1177/1708538115590727.
10. Karaolanis G, Antonopoulos CN, Koutsias S. et al. Outcomes of endosutured aneurysm repair with the Heli-FX Endo Anchor implants. Vascular. 2020;9:1708538120923417. doi: 10.1177/1708538120923417.
11. Marone EM, Freyrie A, Ruotolo C. et al. Expert opinion on hostile neck definition in endovascular treatment of abdominal aortic aneurysms (a Delphi consensus). Ann Vasc Surg. 2020;62:173–182. doi: 10.1016/j.avsg.2019.05.049.
12. Pitoulias GA, Valdivia AR, Hahtapornsawan S. et al. Conical neck is strongly associated with proximal failure in standard endovascular aneurysm repair. J Vasc Surg. 2017;66(6):1686–1695. doi: 10.1016/j.jvs.2017.03.440.
13. Powell JT, Sweeting MJ, Ulug P. et al. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Brit J Surg. 2017;104:166–178. doi: 10.1002/bjs.10430.
14. Ricci C, Ceccherini C, Leonini S. et al. Double renal chimney graft using only femoral approach. J. Cardiovasc. Surg. (Torino). 2011;52:93–97.
15. Ullery BW, Lee JT, Dalman RL. Snorkel/chimney and fenestrated endografts for complex abdominal aortic aneurysms. J Cardiovasc Surg. (Torino). 2015;56(5):707–717.
16. Verhoeven EL, Vourliotakis G, Bos WT. et al. Fenestrated stent grafting for short-necked and juxtarenal abdominal aortic aneurysm: an 8-year single-centre experience. Eur J Vasc Endovasc Surg. 2010;39:529–536. doi: 10.1016/j.ejvs.2010.01.004. 

Результати алкогольної септальної абляції в лікуванні гіпертрофічної кардіоміопатії

Б.М. Тодуров, Г.І. Ковтун, А.В. Хохлов, О.В. Пантазі, А.О. Шпачук, А.Ю. Мельник, А.О. Максаков, А.С. Бацюн

Література   

1. Angelini P. The 1st septal unit in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience. Tex Heart Inst. J.2007;34 (3):336–346.
2. Argulian E, Sherrid MV, Messerli F.H. Misconceptions and Facts About Hypertrophic Cardiomyopathy. Am J Med. 2016;129 (2):148–152. doi: 10.1016/j.amjmed.2015.07.035.
3. Cooper RM, Binukrishnan SR, Shahzad A, Hasleton J, Sigwart U, Stables RH. Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Euro Intervention. 2017;12 (18):e2194–e2203. doi: 10.4244/EIJ-D-15-00159.
4. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G. 2014 ESC Guidelines on diagnosis and managet of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35 (39):2733–2779. doi: 10.1093/eurheartj/ehu284.
5. Holmes DR. Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter. Cardiovasc Interv. 2005;66 (3):375–389. doi: 10.1002/ccd.20500.
6. Houston BA, Stevens GR. Hypertrophic cardiomyopathy: a review. Clin Med Insights Cardiol. 2015;8(1):53–65. doi: 10.4137/CMC.S15717.
7. Khouzam RN, Naidu SS. Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep. 2014;16 (5):478. doi: 10.1007/s11886-014-0478-36.
8. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35 (30):2010–2020. doi: 10.1093/eurheartj/eht439.
9. Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, Agler D, Lytle BW, Lever HM, Desai MY. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography Circ Cardiovasc Imaging. 2015;8 (7):e003132. doi: 10.1161/CIRCIMAGING.115.003132.
10. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J. 2011;75 (1):28–37. doi: 10.1253/circj.cj-10-0962.
11. Sawaya FJ, Louvard Y, Spaziano M, Morice M-C, Hage F, El-Khoury C, Roy A, Garot P, Hovasse T, H Benamer, Unterseeh T, Chevalier B, Champagne S, Piechaud J-F, Blanchard D, Cormier B, Lefèvre T. Shortand long-term outcomes of alcohol septal ablation with the trans-radial versus the trans-femoral approach: A singlecenter-experience. Int J Cardiol. 2016;220:7–13. doi: 10.1016/j.ijcard.2016.06.127.
12. Schuller JL, Zipse MM, Krantz MJ, Blaker B, Salcedo E, Groves BM, Messenger JC, Beaty B, Sauer WH. Incidence and predictors of late complete heart block after alcohol septal ablation treatment of hypertrophic obstructive cardiomyopathy. J Interv Cardiol. 2015;28(1):90–97. doi: 10.1111/joic.12178.
13. Veselka J, Krejčí J, Tomašov P, Zemánek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35 (30):2040–2045. doi: 10.1093/eurheartj/eht495.